Allogeneic Transplantation
Lymphoma Trials (B- and T-cell)
COMIRB: 23-0056
A Phase 3, Open-Label, Randomized Study of A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients with Relapsed or Refractory Non-Hodgkin and Hodgkin Lymphoma (APOLLO)
Principal Investigator: Manali Kamdar
Eligibility: Ages ≥ 18; Cytologically or histologically confirmed diagnosis of NHL, HL or CLL based on the 2022 World Health Organization (WHO) criteria for hematolymphoid neoplasm
COMIRB: 23-1756
A Phase 3 Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia
PI: Manali Kamdar
Eligibility: Ages ≥ 18; Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment; ECOG of ≤2
COMIRB: 22-0939
A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Patients With B-Cell Non-Hodgkin Lymphoma
PI: Manali Kamdar
Eligibility: Ages ≥ 18; ECOG of ≤2
COMIRB: 18-1439
An Open-label, Multicenter, Phase Ib/II trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in combination with Polatuzumab Vedotin in Patients with B-cell Non-Hodgkin Lymphoma
PI: Manali Kamdar
Eligibility: Age ≤18; Histologically confirmed FL, DLBCL, or MCL. At least one prior systemic treatment regimen for DLBCL or FL participants containing an anti-CD20-directed therapy. At least two prior systemic treatment regiments for MCL participants which include 1) anti-CD20-directed therapy, 2) BTK inhibitor, and 3) anthracycline or bendamustine; ECOG of ≤2
COMIRB: 22-1252
A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-cell Malignancies (waveLINE-006)
PI: Steven Bair
Eligibility: Ages ≥ 18; diagnosed aggressive or indolent B-cell malignancies; ECOG of ≤2
COMIRB: 19-3011
A Phase 2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
PI: Manali Kamdar
Eligibility: Ages ≥ 18; Relapsed or refractory follicular lymphoma (FL) (Grade 1, 2 or 3a) or marginal zone lymphoma (MZL) histologically confirmed within 6 months of screening, as assessed by local pathology; Follicular lymphoma patients: Received at least one prior line of systemic therapy; Marginal zone lymphoma patients: Received two or more prior lines of systemic therapy; ECOG of 0 or 1
COMIRB: 21-2578
Phase 1/1b Study of Bispecific CD19 and CD22 Chimeric Antigen Receptor Co-Expressing T Cells (CD19x22 CAR T) in Adolescent and Adult Patients with Relapsed and/or Refractory B-Non-Hodgkin's Lymphoma (B-NHL)
PI: Manali Kamdar
Eligibility: Ages ≥ 16; Relapsed or refractory aggressive B-cell NHL; ECOG of 0 or 1
COMIRB: 21-4327
A Phase I Study with an Expansion Cohort of Duvelisib and Nivolumab in Mycosis Fungoides (MF) and Sézary Syndrome (SS)
PI: Brad Haverkos
Eligibility: Ages ≥ 18; Confirmed MF or SS, stages IIB to IVB with measurable disease and/or detectable blood involvement; at least one line of prior systemic therapy; ECOG of ≤2
COMIRB: 22-0565
An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
PI: Brad Haverkos
Eligibility: Ages ≥ 18; EBV+ relapsed/refractory lymphoma following 2 or more prior systemic therapies; ECOG of ≤2
COMIRB: 22-1202
A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with Relapsed/Refractory Peripheral T-cell Lymphoma
PI: Brad Haverkos
Eligibility: Ages ≥ 18; histologically R/R PTCL; ECOG of ≤2
Request an Appointment
If you would like to schedule an appointment, please give us a call.
Our intake coordinator will help you navigate the process of becoming a new patient including helping you obtain the necessary referrals, get the necessary medical records transferred, and coordinate care with your existing physicians. We are available to answer your questions about our clinic, your treatment, and participation in ongoing clinical trials.